Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
성장 중
회사는 성장 단계에 있으며, 최신 연간 수익은 미화 21.80K에 달합니다.
고수익 성장
회사의 순이익은 업계 선두를 달리고 있으며, 최근 연간 순이익은 미화 21.80K에 달합니다.
과대 평가된
회사의 최신 PE은 -0.85로, 최근 3년 기준 높은 백분위 범위에 속합니다.
기관 매수
최신 기관 보유 주식 수는 2.06M주이며, 전 분기 대비 42.85% 증가했습니다.